Merck lawsuit over Fosamax ends in mistrial
NEW YORK (Reuters), Sep 11 – A lawsuit alleging that Merck & Co.’s osteoporosis drug Fosamax caused jaw damage ended in a mistrial on Friday. U.S. District Judge John Keenan declared the mistrial two days giving the New York jury considering the case a “cooling off period” in light of supposed acrimony among jurors. A Merck lawyer on Wednesday referred to an “unsubstantiated claim” of a chair being thrown in

